The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

With 6.5% yields or better, these stocks offer four times the payout of the typical blue chip. As the end of the 90-day pause on reciprocal tariffs approaches, investors aren't sure what will ...

Genes and Genetics News. Read today's medical research in genetics including what can damage genes, what can protect them, and more.

The gene therapy launched in the US last year with a $3.5 million price tag as a one-time therapy for adults with moderate to severe haemophilia B who need factor IX (FIX) replacement therapy, but ...

Lilly is one of a clutch of companies looking to develop gene therapies for deafness caused by OTOF mutations, alongside the likes of Regeneron – which added a candidate called DB-OTO from its ...

NEW YORK, June 23, 2025 /PRNewswire/ -- Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, ...